E-viri
Recenzirano
-
Bartlett, Nancy L.
The New England journal of medicine, 12/2022, Letnik: 387, Številka: 24Journal Article
Harnessing the power of a patient’s own T cells has revolutionized the treatment of many cancers, including lymphoma. The most broadly applicable T-cell–directed therapies are the programmed death 1 (PD-1) inhibitors, a remarkably effective wake-up call for T cells that have been lulled to sleep by cancer cells. Although PD-1 inhibitors have improved outcomes in Hodgkin’s lymphoma, they are inactive in most non-Hodgkin’s lymphomas. An alternative T-cell strategy — chimeric antigen receptor (CAR) T cells, which are autologous T cells genetically engineered to target B-cell antigens — has shown promise in multiple subtypes of B-cell lymphoma. Mature data on CAR . . .
